Benzinga | Aug 5, 2021 06:53AM EDT

Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $18

Needham analyst Serge Belanger maintains Flexion Therapeutics (NASDAQ:FLXN) with a Buy and lowers the price target from $20 to $18.